ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

3-(2-(4-quinolin-3-yl)benzyl-1-oxoisoindolin-6-yl)-N-hydroxy-acrylamide

Its studies are mostly in Hidradenitis Suppurativa · Crohn Disease, led by Shattuck Labs.

Drug page3-(2-(4-quinolin-3-yl)benzyl-1-oxoisoindolin-6-yl)-N-hydroxy-acrylamide: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Aug 4, 20263 company-led studies, 2 open or runningNext primary completion: Feb 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Shattuck Labs32 open or runningphase 2since Aug 4, 2026Aug 28, 2025Feb 2028phase 2 · NCT07934017

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 28, 2025First study: phase 1 study in Healthy VolunteersFirst studyNCT07158437 · 72 enrolled · United States
  2. Aug 4, 2026Phase 2 study in Crohn DiseasePhase 2 reachedNCT07753850 · 232 planned · United States
  3. Nov 6, 2026Phase 2 study in Hidradenitis SuppurativaNCT07934017 · 150 planned

Ahead

  1. Feb 2028Primary completion: phase 2 study in Hidradenitis SuppurativaNCT07934017
  2. Jul 2028Primary completion: phase 2 study in Crohn DiseaseNCT07753850

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07934017Hidradenitis Suppurativa2Not yet recruitingFeb 2028150
NCT07753850Crohn Disease · United States2RecruitingJul 2028232
NCT07158437Healthy Volunteers · United States1CompletedJul 16, 202672

How it is read

Names in the registry

  • “SL-325”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.